Results 1 - 20 of 111 in Geron
-
Geron Corporation to Present at Lazard Capital Markets Healthcare Conference
Geron Corporation today announced that Thomas B. Okarma, Ph.D., M.D., president and chief executive officer, will present an update of the company's oncology programs at 3:00 p.m. ET on Wednesday, November 19, ...
Comment?
-
Geron Corporation to Present at Lazard Capital Markets Healthcare Conference
Lazard Capital Markets 5th Annual Healthcare Conference - Geron Corporation today announced that Thomas B. Okarma, Ph.D., M.D., president and chief executive officer, will present an update of the company"s ...
Comment?
-
Geron to Present at Rodman and Renshaw Annual Global Investment Conference
The update will focus on a review of Geron's human embryonic stem cell development program for spinal cord injury .
Comment?
-
Geron to Present at Rodman & Renshaw Annual Global Investment Conference
Geron Corporation today announced that Thomas B. Okarma, Ph.D., M.D., president and chief executive officer, will present an update of the company ' s human embryonic stem cell development programs at 12:00 ...
Comment?
-
Geron Scientists and Collaborators Demonstrate TAT2 - A Small...
Nov 10, 2008 - Geron Corporation today announced the publication of preclinical data on TAT2, a small molecule telomerase activator.
Comment?
-
Beacon Equity Issues Technical Trade Alerts on Market Movers: ASTM, CMLS, CSUN, JASO, GERN, BRKR
... Cumulus Media Inc. (Nasdaq: CMLS), China Sunergy Co. Ltd. (Nasdaq: CSUN), JA Solar Holdings Co. Ltd. (Nasdaq: JASO), Geron Corp. (Nasdaq: GERN) and Bruker Corp. (Nasdaq: BRKR). Join the fastest growing investment community at: ...
Comment?
-
Geron Q3 loss widens to $17.2M
Biopharmaceutical company Geron Corp. on Thursday reported a third quarter loss of $17.2 million, or 22 cents a share, compared to a loss of $12.8 million, or 17 cents a share in the same period last year.
Comment?
-
Geron's Q3 loss grows to $17.2M
Geron Corp. lost $17.2 million in the September quarter, up from a loss of $12.8 million in the same quarter a year earlier.
Comment?
-
Geron Corporation Reports 2008 Third Quarter Financial Results and Events
Geron Corporation today reported financial results for the three and nine months ended Sept.
Comment?
-
Survival Of Diabetic Mice Improved After Transplantation Of Human Embryonic Stem Cell Derived ILCs
... the need for insulin administration, but cell availability is severely limited," said Thomas B. Okarma, Ph.D., M.D., Geron's president and chief executive officer. "The in vivo characterization of hESC-derived islet-like clusters is an important ...
Comment?
-
Survival Of Diabetic Mice Improved After Transplantation Of Human Embryonic Stem Cell Derived ILCs
... the need for insulin administration, but cell availability is severely limited," said Thomas B. Okarma, Ph.D., M.D., Geron's president and chief executive officer. "The in vivo characterization of hESC-derived islet-like clusters is an important ...
Comment?
-
Geron Corporation to Present at 7th Annual Bio Investor Forum
MENLO PARK, Calif. - Geron Corporation today announced that Thomas B. Okarma, Ph.D., M.D., president and chief executive officer, will present an update of the company ' s product development programs at 9:00 ...
Comment?
-
Geron Scientists and Collaborators Demonstrate Activity of Pancreatic ...
... the need for insulin administration, but cell availability is severely limited, " said Thomas B. Okarma, Ph.D., M.D., Geron ' s president and chief executive officer. " The in vivo characterization of hESC-derived islet-like clusters is an important ...
Comment?
-
First stem-cell therapy looks for FDA nod
... may soon get FDA clearance to continue its trial, potentially setting standards for future stem cell-based drugs. Geron Corp. of Menlo Park, which is developing an embryonic stem cell-derived spinal cord injury treatment, could get the go-ahead from ...
Comment?
-
Geron Initiates Clinical Trial Of GRN163L In Combination With...
Geron Corporation today announced that it has enrolled the first multiple myeloma patient in a clinical trial of its telomerase inhibitor drug, GRN163L, in combination with other treatments.
Comment?
-
Geron Initiates Clinical Trial Of GRN163L In Combination With...
Main Category: Blood / Hematology Also Included In: Lymphoma / Leukemia ; Clinical Trials / Drug Trials ; Cancer / Oncology Article Date: 21 Oct 2008 - 6:00 PDT Geron Corporation today announced that it has ...
Comment?
-
Breast Cancer - Data Show Synergistic Activity Of Telomerase...
Main Category: Breast Cancer Also Included In: Cancer / Oncology ; Biology / Biochemistry Article Date: 16 Oct 2008 - 7:00 PDT Geron Corporation today announced the publication of preclinical data demonstrating ...
Comment?
-
Breast Cancer - Data Show Synergistic Activity Of Telomerase...
Geron Corporation today announced the publication of preclinical data demonstrating that its telomerase inhibitor drug, GRN163L, significantly boosts the effects of trastuzumab against HER2-positive breast ...
Comment?
-
Geron's GRN163L Sensitizes Resistant Breast Cancer Cells to Trastuzumab in Preclinical Study
Oct 15, 2008 - Geron Corporation today announced the publication of preclinical data demonstrating that its telomerase inhibitor drug, GRN163L, significantly boosts the effects of trastuzumab ) against ...
Comment?
-
Stem Cell Trendsetters in Neurology and Psychiatry Analyzed by NeuroInsights
... BrainCells, Inc., BrainStorm Cell Therapeutics, California Stem Cell Inc., Cell Cure Neurosciences, CellMed AG, Geron Corporation (Nasdaq: GERN), International Stem Cell Corporation, NeuralStem, NeuroGeneration, NeuroNascent, NeuroNova AB, Neuronyx, ...
Comment?
Geron Forum
Most Popular